Boehringer Ingelheim and Yale Collaborate to Investigate Immunotherapies
Boehringer Ingelheim announced that it would collaborate with Yale University to research novel therapeutic targets in immune-modulation.
On January 13, 2015, Boehringer Ingelheim (BI) announced that it would collaborate with Yale University to research novel therapeutic targets in immune-modulation, or treatments aimed at harnessing a patient’s immune system for tumor control, stabilization, and eradication of the disease, according to the British Journal of Cancer. BI will provide Yale with research funding for an agreed upon number of projects, while working closely with the Yale scientists to advance the research. The terms of the agreement also give BI the option to obtain an exclusive license from Yale for all of the programs.
"This collaboration will help us to identify important pathways, and what the biological application of modulating those pathways will be. We will investigate whether these new pathways could become future drug targets,” said Lieping Chen, MD, United Technologies chair in cancer research, professor of immunobiology and director of cancer immunology at the Yale Cancer Center, Yale University School of Medicine, in a press release.
Source: Boehringer Ingelheim
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
